Emergent BioSolutions Inc. (NYSE:EBS) Shares Purchased by SG Americas Securities LLC

SG Americas Securities LLC grew its position in shares of Emergent BioSolutions Inc. (NYSE:EBS) by 250.1% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 60,724 shares of the biopharmaceutical company’s stock after purchasing an additional 43,378 shares during the period. SG Americas Securities LLC owned approximately 0.12% of Emergent BioSolutions worth $507,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the company. Avidian Wealth Solutions LLC purchased a new position in shares of Emergent BioSolutions during the 1st quarter valued at approximately $33,000. Tidal Investments LLC acquired a new position in shares of Emergent BioSolutions in the 1st quarter worth approximately $34,000. CWM LLC increased its holdings in shares of Emergent BioSolutions by 32,706.7% in the 2nd quarter. CWM LLC now owns 4,921 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 4,906 shares during the last quarter. Meeder Asset Management Inc. bought a new position in Emergent BioSolutions during the second quarter worth $41,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in Emergent BioSolutions during the first quarter worth $57,000. Hedge funds and other institutional investors own 78.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on EBS. Rodman & Renshaw reissued a “buy” rating and issued a $16.00 target price on shares of Emergent BioSolutions in a report on Friday, September 13th. Benchmark reissued a “buy” rating and issued a $8.00 price target on shares of Emergent BioSolutions in a report on Friday, August 16th.

Emergent BioSolutions Trading Up 2.1 %

NYSE:EBS opened at $9.19 on Wednesday. The stock has a fifty day simple moving average of $8.18 and a 200 day simple moving average of $6.89. The firm has a market capitalization of $481.57 million, a price-to-earnings ratio of -0.83 and a beta of 1.59. The company has a quick ratio of 0.54, a current ratio of 1.06 and a debt-to-equity ratio of 1.16. Emergent BioSolutions Inc. has a 1-year low of $1.42 and a 1-year high of $15.10.

Emergent BioSolutions (NYSE:EBS) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($2.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($1.35). The firm had revenue of $254.70 million during the quarter, compared to analyst estimates of $199.47 million. Emergent BioSolutions had a negative return on equity of 34.38% and a negative net margin of 53.26%. During the same period in the prior year, the business posted ($1.06) EPS. Sell-side analysts forecast that Emergent BioSolutions Inc. will post -1.3 earnings per share for the current year.

Emergent BioSolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.